Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nipocalimab for prevention of severe fetal and neonatal alloimmune thrombocytopenia in high-risk pregnancies
MOH_2024-12-22_013801Phase 3Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fetomaternal alloimmune thrombocytopenia (FMAIT) comparing Nipocalimab with Placebo (2 arms). Started Dec 2024; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on MOH_2024-12-22_013801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-22_013801.